Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

Sapphire Bioscience Holding ApS - Group Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 N/A 2019 N/A 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   0.0% 0.0% 20.7% 1.0% 0.9% 0.9% 5.0% 4.9%   Credit score (0-100)   0 0 5 84 90 87 44 44   Credit rating   N/A N/A B A A A BBB BBB   Credit limit (kDKK)   8,753.4 8,976.8 0.0 9,574.0 19,510.8 15,090.8 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 N/A 2019 N/A 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   0.0 0.0 0.0 108,874 136,234 137,367 0.0 0.0   EBITDA   0.0 0.0 0.0 64,864 80,232 58,577 0.0 0.0   EBIT   0.0 0.0 0.0 48,118 57,604 41,042 0.0 0.0   Pre-tax profit (PTP)   27,949.0 24,389.0 25,843.0 47,193.0 59,552.0 39,356.0 0.0 0.0   Net earnings   27,949.0 24,389.0 25,843.0 37,940.0 46,684.0 28,464.0 0.0 0.0   Pre-tax profit without non-rec. items   0.0 0.0 0.0 47,193 59,552 39,356 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 N/A 2019 N/A 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 32,046 29,605 8,254 0.0 0.0   Shareholders equity total   86,536 88,745 98,630 137,382 184,234 150,076 69,959 69,959   Interest-bearing liabilities   0.0 0.0 0.0 15,908 1,686 88.0 0.0 0.0   Balance sheet total (assets)   0.0 0.0 14,513 199,753 233,883 222,609 69,959 69,959   Net Debt   0.0 0.0 -14,513 -32,452 -47,558 -43,895 -69,389 -69,389     See the entire balance sheet 1000.0 Volume  2018 N/A 2019 N/A 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   0.0 0.0 0.0 108,874 136,234 137,367 0.0 0.0   Gross profit growth   0.0% 0.0% 0.0% 0.0% 25.1% 0.8% -100.0% 0.0%   Employees   0 0 0 56 67 81 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 19.6% 20.9% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   0 0 14,513 199,753 233,883 222,609 69,959 69,959   Balance sheet change%   0.0% 0.0% 0.0% 1,276.4% 17.1% -4.8% -68.6% 0.0%   Added value   0.0 0.0 0.0 64,864.0 74,350.0 58,577.0 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 63,151 -30,833 -35,661 -52,996 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   0.0 0.0 0.0 1.0 2.0 3.0 0.0 0.0   1000.0 Profitability  2018 N/A 2019 N/A 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   0.0% 0.0% 0.0% 44.2% 42.3% 29.9% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   0.0% 0.0% 0.0% 44.9% 28.0% 20.1% 0.0% 0.0%   ROI %   0.0% 0.0% 0.0% 57.1% 35.1% 26.1% 0.0% 0.0%   ROE %   32.3% 13.9% 13.8% 32.2% 29.0% 17.0% 0.0% 0.0%   1000.0 Solidity  2018 N/A 2019 N/A 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   100.0% 100.0% 100.0% 76.9% 86.4% 79.7% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   0.0% 0.0% 0.0% -50.0% -59.3% -74.9% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.0% 11.6% 0.9% 0.1% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 0.0% 0.0% 11.6% 12.6% 747.8% 0.0% 0.0%   1000.0 Liquidity  2018 N/A 2019 N/A 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   0.0 0.0 0.0 1.9 4.3 3.3 0.0 0.0   Current Ratio   0.0 0.0 0.0 1.9 3.7 2.6 0.0 0.0   Cash and cash equivalent   0.0 0.0 14,513.0 48,360.0 49,244.0 43,983.0 0.0 0.0   1000.0 Capital use efficiency  2018 N/A 2019 N/A 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   0.0 0.0 14,513.0 57,052.0 116,361.0 101,980.0 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 N/A 2019 N/A 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 0 0 1,158 1,110 723 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 1,158 1,197 723 0 0   EBIT / employee   0 0 0 859 860 507 0 0   Net earnings / employee   0 0 0 678 697 351 0 0